NCT04302181 is a EARLY_PHASE1 clinical trial of Ropivacaine injection in Stress Disorders, Post-Traumatic, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT04302181?

NCT04302181 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT04302181?

Interventions in NCT04302181: Ropivacaine injection.

What condition does NCT04302181 study?

NCT04302181 studies Stress Disorders, Post-Traumatic.

Is NCT04302181 still recruiting?

NCT04302181 is currently completed. Last updated 9 September 2022.

Last reviewed 2022-09-09 · How we verify

NCT04302181

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD

Completed EARLY_PHASE1 Last updated 9 September 2022

What this trial tests

EARLY_PHASE1 trial testing Ropivacaine injection in Stress Disorders, Post-Traumatic in 12 participants. Completed in 3 December 2021.

Timeline

5 October 2020

Primary endpoint
1 July 2021

3 December 2021

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	5 October 2020
Primary completion	1 July 2021
Estimated completion	3 December 2021
Sites	2 locations across United States

Drugs / interventions tested

Ropivacaine injection — full drug profile →

Conditions studied

Stress Disorders, Post-Traumatic — all drugs for Stress Disorders, Post-Traumatic →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

Adults 18 to 65, any sex, with Stress Disorders, Post-Traumatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a small, open-label treatment study that tests the potential safety and treatment effectiveness of a stellate ganglion block combined with Massed Prolonged Exposure (PE). Each of the 12 participants will receive ten 90-minute sessions of Massed Prolonged Exposure and an injection of a stellate ganglion block between the first and second PE sessions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Stellate Ganglion Block for Psychiatric Disorders: A Systematic Review of the Clinical Research Landscape.
Kerzner J, Liu H, Demchenko I, Sussman D, et al · · 2021 · cited 15× · PMID 34901677 · DOI 10.1177/24705470211055176

Verify or expand the search:

Other trials of Ropivacaine injection

Trials testing the same drug.

NCT06299137 — Ultrasound Guided Serratus Anterior Plane Block in ED Patients With Rib Fractures · EARLY_PHASE1 · completed
NCT05889741 — Combining Stellate Ganglion Block With Prolonged Exposure for PTSD · Phase 2 · recruiting
NCT06189781 — Pain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy · Phase 4 · recruiting
NCT06288841 — Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in · NA · unknown
NCT06048874 — FNB in ACL Recon Under SA · NA · not yet recruiting

Other recruiting trials for Stress Disorders, Post-Traumatic

Currently open trials in the same condition.

NCT07422077 — Impact of ERCS on Perceived Stress in Patients Hospitalized in the Post-resuscitation Rehabilitation Service · NA · recruiting
NCT07010770 — SMART Therapist Training: A Hybrid Factorial-SMART Design · NA · recruiting
NCT06852469 — Computational Assessment of GABA Receptor Modulation in PTSD · Phase 4 · recruiting
NCT06000475 — Enhancing Memory in CPT for PTSD · NA · recruiting
NCT06355284 — Overcontrol and Suicide in PTSD · active not recruiting

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04302181 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 9 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04302181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing